Drug Trial Radar · NCT01422304
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
Last checked: Nov 19, 2026Latest source record: Feb 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,198
Actual
Start
Oct 12, 2011
Primary completion
Sep 26, 2012
Study completion Sep 26, 2012
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on coagulation parameters in participants undergoing hip fracture surgery or joint (hip/knee) replacement surgery with neuromuscular blockage induced by rocuronium or vecuronium.
Conditions
- Neuromuscular Blockade
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Blood Coagulation
- Antithrombotic Agents
Interventions
SugammadexDrug
Sugammadex 4 mg/kg intravenously
neostigmine and glycopyrrolate or atropineDrug
Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
Placebo to neostigmineDrug
Normal saline (NaCl 0.9%)
Placebo to sugammadexDrug
Normal saline (NaCl 0.9%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug AdministrationTime frame: Up to 24 hours post study drug administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.